Search results
Showing 361 to 375 of 537 results for syndrome
Stapled transanal rectal resection for obstructed defaecation syndrome (IPG351)
Interventional procedures, IPG351 - Issued: June 2010 --> We have moved interventional procedures guidance 351 to become HealthTech guidance 224. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Stapled transanal rectal resection for obstructed defaecation syndrome (IPG169)
This guidance has been updated and replaced by NICE HealthTech guidance 224.
Arthroscopic femoro-acetabular surgery for hip impingement syndrome (IPG213)
This guidance has been updated and replaced by NICE HealthTech guidance 273.
Open femoro-acetabular surgery for hip impingement syndrome (IPG203)
This guidance has been updated and replaced by NICE HealthTech guidance 270.
Laparoscopic renal denervation for loin pain haematuria syndrome (IPG709)
We have moved interventional procedures guidance 709 to become HealthTech guidance 596. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Phrenic nerve pacing for congenital central hypoventilation syndrome (IPG790)
We have moved interventional procedures guidance 790 to become HealthTech guidance 725. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Teduglutide for treating short bowel syndrome (terminated appraisal) (TA690)
This guidance has been updated and replaced by NICE technology appraisal guidance TA804.
This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition. It also aims to help them provide those at high risk with an effective and appropriate intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The recommendations in this guideline can be used alongside the NHS Health Check programme .
Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.
View recommendations for TA223Show all sections
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults.
Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)
Evidence-based recommendations on lenvatinib (Lenvima) for untreated advanced hepatocellular carcinoma in adults.
Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome (IPG362)
Interventional procedures, IPG362 - Issued: October 2010 --> We have moved interventional procedures guidance 362 to become HealthTech guidance 235. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Adrenal insufficiency: identification and management (NG243)
This guideline covers identifying and managing adrenal insufficiency (hypoadrenalism) in babies, children, young people and adults. It aims to improve the treatment of primary, secondary and tertiary adrenal insufficiency, and the prevention and management of adrenal crisis.
Discontinued Reference number: GID-TA10767
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)
Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.